A CXCR1/2 inhibitor (ladarixin), which reduces the polarization and migration of M2-like macrophages, has been shown to enhance the anti-tumor effect of PD-1 inhibitors when combined166; however, no relevant clinical trials are underway. This evidence concerns the gene PDCD1 and neoplasm.